We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tolerability and Safety of An Infant Formula

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00938483
Recruitment Status : Completed
First Posted : July 14, 2009
Last Update Posted : July 15, 2009
Information provided by:
Perrigo Nutritionals

July 7, 2009
July 14, 2009
July 15, 2009
August 2007
September 2008   (Final data collection date for primary outcome measure)
Infant reactivity to an extensively hydrolyzed infant formula [ Time Frame: 29 days ]
Same as current
Complete list of historical versions of study NCT00938483 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Tolerability and Safety of An Infant Formula
A Multicenter, Single-blind, Randomized, Phase II Study of the Tolerability and Safety of NPS-202 in Infants With Clinically Diagnosed Cow's Milk Allergy
The purpose of this study is to evaluate an extensively hydrolyzed formula in infants with cow's milk allergy.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Milk Hypersensitivity
Other: Nutramigen Lipil (Infant formula)
Other Name: Extensively hydrolyed infant formula (Nutramigen Lipil)
  • Experimental: Extensively hydrolyzed infant formula
    New extensively hydrolyzed formula, NPS-202
    Intervention: Other: Nutramigen Lipil (Infant formula)
  • Active Comparator: Infant formula - Extensively hydrolyzed Nutramigen Lipil
    Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
    Intervention: Other: Nutramigen Lipil (Infant formula)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2009
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • clinically diagnosed CMA
  • </= 12 weeks at time of study entry
  • full-term infant
  • must be willing to use provided formula as sole source of nutrition
  • other than CMA, infant must be otherwise healthy

Exclusion Criteria:

  • underlying or confounding gastrointestinal abnormalities
  • infants born from an addictive situation, HIV positive
  • if parent/guardian is considered likely to be non-compliant with the protocol requirements
Sexes Eligible for Study: All
up to 12 Weeks   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Cynthia Barber, PhD, Vice President, Regulatory, Medical and Clinical Affairs, PBM Products, LLC
Perrigo Nutritionals
Not Provided
Study Director: Cynthia M Barber, PhD Perrigo Nutritionals
Perrigo Nutritionals
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP